{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"description":"Common Toxicity Criteria, also referred to as the Common Terminology Criteria for Adverse Events (CTCAE), is a standardized classification of side effects used in assessing drugs for cancer therapy. Cohorts A, B, C, and D.","groups":[{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG000","title":"Cohort A: Liposarcoma"},{"description":"21 days on and 7 days off\n\nPlacebo\n\nPlacebo: 21 days on and 7 days off","id":"OG001","title":"Cohort A: Liposarcoma, Placebo"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG002","title":"Cohort B: Osteosarcoma"},{"description":"21 days on and 7 days off\n\nPlacebo\n\nPlacebo: 21 days on and 7 days off","id":"OG003","title":"Cohort B: Osteosarcoma, Placebo"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG004","title":"Cohort C: Ewing Sarcoma"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG005","title":"Cohort D: Rhabdomyosarcoma"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG006","title":"Cohort E: Mesenchymal Chondrosarcoma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts.","type":"SECONDARY","unitOfMeasure":"Participants"}